Capricor Therapeutics, Inc. CAPR
10.38 USD -0.84 (-7.49%)
Nov 12, 2026, 1:49 PM EST
9.87 Day range 10.95
2.96 52-week range 40.37
- YTD
- -64.03%
- 1 year
- +76.83%
News
benzinga.com Jones Trading Upgrades Capricor Therapeutics to Buy, Announces $25 Price Target Jones Trading analyst Catherine Novack upgrades Capricor Therapeutics (NASDAQ:CAPR) from Hold to Buy and announces $25 price target.
benzinga.com Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trading higher Wednesday despite the company missing earnings per share estimates in its third-quarter results Tuesday after the market closed.
benzinga.com Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss Capricor Therapeutics shares are trading higher Wednesday despite a wider-than-expected Q3 loss Tuesday after the market closed.
seekingalpha.com Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
marketbeat.com Capricor Therapeutics Q3 Earnings Call Highlights Capricor Therapeutics NASDAQ: CAPR is awaiting a Nov. 22 Food and Drug Administration decision on Deramiocel for Duchenne muscular dystrophy, as the company prepares for a potential launch while…
benzinga.com Capricor Therapeutics Q3 2026 Earnings Call Transcript Capricor Therapeutics (NASDAQ:CAPR) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.This transcript is brought to you by Benzinga APIs. For…
benzinga.com Capricor Therapeutics Q3 EPS $(0.73) Misses $(0.05) Estimate Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.05) by 1360 percent. This is a 35.19 percent decrease over losses…
globenewswire.com Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
globenewswire.com Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
benzinga.com What's Going On With Capricor Therapeutics Stock Monday? Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
benzinga.com Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima -24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year--At 24 Months, Both Groups Showed Slower Decline…
benzinga.com Capricor Therapeutics Stock Surges: What's Going On? Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
benzinga.com Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
benzinga.com Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.
benzinga.com B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21 B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
benzinga.com Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25 Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
benzinga.com Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings.…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and…
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com Why Is Capricor Therapeutics Stock Trading Higher on Monday? Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.- benzinga.com Capricor Therapeutics Says FDA Extends PDUFA Target Action Date For Its BLA For Deramiocel, Investigational Cell Therapy For Duchenne Muscular Dystrophy, From August 22 To November 22 – New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –SAN DIEGO, Aug. 24, 2026 (GLOBE…
benzinga.com Activist Investor Sounds Alarm on Capricor’s Cash Burn Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR) as expenses rise.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ:CAPR) ("Capricor" or the "Company"), today issued a
benzinga.com H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
benzinga.com Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
benzinga.com This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…- benzinga.com Market-Moving News for August 14th AMAT: -5% | Applied Materials shares are trading lower after the company reported Q3 financial results. Weakness may be related to elevated investor expectations. AKAN: 100% | Akanda shares are…
benzinga.com Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28 Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.- benzinga.com Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
- benzinga.com Capricor Therapeutics Q2 2026 Earnings Call Transcript Capricor Therapeutics (NASDAQ:CAPR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by…
benzinga.com Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over…
benzinga.com Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.- benzinga.com Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2 Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap…
benzinga.com Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectations, Columbus McKinnon and Xerox report strong earnings.
benzinga.com Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results US stocks rise with Nasdaq up 600 points, Dow up 0.69% and S&P 500 up 1.29%. Tech shares up 5%, communication services down 3.3%. Microsoft jumps 15% after strong earnings.
benzinga.com Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite published Phase 3 HOPE-3 trial results.- benzinga.com Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5 Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.
benzinga.com Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…
- benzinga.com 'FDA panel votes against Capricor's Duchenne heart disease therapy'- Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-against-capricors-duchenne-heart-disease-therapy-2026-07-29/